CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market buy Director bought 1,000 shares at $0.69 ($688)
- 4 Open-market buy Director bought 334 shares at $0.91 ($304)
- 4 Open-market buy Director bought 2,000 shares at $1.06 ($2,127)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other disposition Director disposed of 661,168 shares (other)
- 4 Open-market buy Director bought 5,000 shares at $1.02 ($5,093)
- 4 Open-market buy 10% owner bought 700 shares at an average $0.91 ($635)
- 4 Open-market buy Chief Financial Officer bought 53,000 shares at $0.19 ($10,234)
- 4 Open-market buy 10% owner bought 18,000 shares at $0.59 ($10,705)
- 4 Open-market buy Chief Executive Officer bought 37,000 shares at $0.54 ($19,999)
- 4 Open-market buy Director bought 10,000 shares at $0.44 ($4,350)
- 4 Open-market buy 10% owner bought 9,000 shares at an average $0.46 ($4,155)
- 4 Option exercise Director acquired 500,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 1,000 shares at $0.60 ($597)
- 4 Open-market buy 10% owner bought 4,000 shares at an average $0.57 ($2,277)
- 4 Open-market buy 10% owner bought 5,000 shares at $0.81 ($4,050)
- 4 Open-market buy 10% owner bought 43,000 shares at an average $0.86 ($36,773)
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
Page 3 of 9 · 170 filings